Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
Authors
Ramasamy, KarthikSadler, Ross
Jeans, Sally
Weeden, Paul
Varghese, Sherin
Turner, Alison
Larham, Jemma
Gray, Nathanael
Carty, Oluremi
Barrett, Joe
Bowcock, Stella
Oppermann, Udo
Cook, Gordon
Kyriakou, Chara
Drayson, Mark
Basu, Supratik
Moore, Sally
McDonald, Sarah
Gooding, Sarah
Javaid, M. Kassim
Issue Date
2022-01-22
Metadata
Show full item recordAbstract
Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination. Using a prospective study of myeloma patients in UK Rudy Study cohort, we assessed humoral and Interferon gamma release assay (IGRA) cellular immune responses to COVID-19 vaccination post second COVID-19 vaccine administration. We report data from 214 adults with myeloma (n=204) or smouldering myeloma (n=10) who provided blood samples at least 3 weeks after second vaccine dose. Positive Anti-Spike antibody levels (> 50 IU/ml) were detected in 189/203 (92.7%), positive IGRA responses were seen in 97/158 (61.4%) myeloma patients. Only 10/158 (6.3%) patients were identified to have both a negative IGRA and negative Anti-Spike protein antibody response. 95/158 (60.1%) patients produced positive results for both anti-Spike protein serology and IGRA. After adjusting for disease severity and myeloma therapy, poor humoral immune response was predicted by male gender. Predictors of poor IGRA included anti-CD38/ anti-BCMA therapy and Pfizer-BioNTech (PB) vaccination. Further work is required to understand the clinical significance of divergent cellular response to vaccination.Citation
Ramasamy, K., Sadler, R., Jeans, S. et al. (2022) Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. British Journal of Haematology, 197(3), pp. 293-301. https://doi.org/10.1111/bjh.18066Publisher
WileyJournal
British Journal of HaematologyAdditional Links
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18066Type
Journal articleLanguage
enDescription
© 2022 The Authors. Published by Wiley. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1111/bjh.18066ISSN
0007-1048Sponsors
Funding for this study has been received from Blood Cancer Vaccine Consortium and Janssen UK. RUDY platform has been funded by NIHR.ae974a485f413a2113503eed53cd6c53
10.1111/bjh.18066
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/